SAN DIEGO, May 28, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr.
Helen Torley, president and chief
executive officer, will be participating in the following investor
conferences:
- Jefferies Virtual Healthcare Conference at 10:00 a.m. ET / 7:00 a.m.
PT on Thursday, June 4, 2020
- Goldman Sachs 41st Annual Healthcare Conference at
4:40 p.m. ET / 1:40 p.m. PT on Wednesday, June 10, 2020
A live webcast of each event can be accessed through the
"Investors" section of Halozyme's website (www.halozyme.com), and
an archive will be made available for 90 days following each event.
To access a live webcast, please visit Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce hours-long
treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via three commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary enzyme
rHuPH20 forms the basis of the ENHANZE® technology and is used to
facilitate the delivery of injected drugs and fluids, potentially
reducing the treatment burden of other drugs to patients. Halozyme
has licensed its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme
derives revenues from these collaborations in the form of
milestones and royalties as the Company's partners make progress
developing and commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-virtual-investor-conferences-301066785.html
SOURCE Halozyme Therapeutics, Inc.